EyePoint Pharmaceuticals (STU:PV3) 3-Year Revenue Growth Rate : -23.90% (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is EyePoint Pharmaceuticals 3-Year Revenue Growth Rate?

EyePoint Pharmaceuticals's Revenue per Share for the three months ended in Dec. 2023 was €0.24.

During the past 12 months, EyePoint Pharmaceuticals's average Revenue per Share Growth Rate was 6.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was -23.90% per year. During the past 5 years, the average Revenue per Share Growth Rate was 1.90% per year. During the past 10 years, the average Revenue per Share Growth Rate was -1.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of EyePoint Pharmaceuticals was 351.40% per year. The lowest was -58.10% per year. And the median was 16.80% per year.

Competitive Comparison of EyePoint Pharmaceuticals's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, EyePoint Pharmaceuticals's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

EyePoint Pharmaceuticals's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EyePoint Pharmaceuticals's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where EyePoint Pharmaceuticals's 3-Year Revenue Growth Rate falls into.

EyePoint Pharmaceuticals 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

EyePoint Pharmaceuticals (STU:PV3) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

EyePoint Pharmaceuticals 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

EyePoint Pharmaceuticals (STU:PV3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (STU:PV3) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

EYPT:USA PV3B:Germany

Address

480 Pleasant Street, Suite B300, Watertown, MA, USA, 02472

Website

https://www.eyepointpharma.com

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

EyePoint Pharmaceuticals (STU:PV3) Headlines

No Headlines